Highlighting transformative innovations from PCR London Valves 2025, this session features advanced technologies such as the Luna TMVR with its unique intuitive design, the novel Tripair technology for tricuspid therapy, and insights into right heart remodeling following transcatheter tricuspid valve interventions with the DUO system, showcasing...

This session presents featured research on Transcatheter Aortic Valve Implantation (TAVI), analyzing clinical impacts of prosthesis oversizing, same-day discharge experiences, and comparative outcomes of intra-annular versus supra-annular self-expanding valves. It also reviews nationwide TAVR data from Germany and meta-analyses assessing TAVI performance in centers without on-site...

This session addresses contemporary challenges in TAVI, including management of acute valve syndrome through service innovations and the application of Valvosoft non-invasive ultrasound therapy in severe aortic stenosis. It also explores complications such as infective endocarditis post-TAVI, evaluates the feasibility of same-day discharge protocols, and assesses...

This session focuses on the interplay between TAVI and coronary artery disease, discussing high-risk TAVR cases requiring complex left main PCI with prophylactic ECMO support. It provides guidance on timing and strategies for managing concomitant coronary artery disease in TAVI patients, addressing the critical decision-making process...

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.